Northwest Parkinson's Foundation:
By activating the alpha-7 nicotinic receptor, nicotine—which increases dopamine levels in the brain—appears to be able to rescue mouse dopaminergic neurons cultured under conditions that favor their loss. Genetically engineered mouse cells that lacked a specific nicotine receptor (the alpha-7 subtype), however, were unaffected by nicotine treatment.
The findings suggest that new Parkinson’s therapies may be developed to target nicotine receptors, FierceBiotech reports. “This study raises the hope for a possible neuroprotective treatment,” said co-author Patrick P. Michel of the Institut du Cerveau et de la Moelle Épinière, Hôpital de la Salpêtrière, in Paris, France, in a statement.
But this is not an endorsement for cigarettes, FASEB noted. “If you’re a smoker, don’t get too excited,” Gerald Weissmann, editor-in-chief of The FASEB Journal, said in a statement. “Even if smoking protects you from Parkinson’s, you might not live long enough to develop the disease because smoking greatly increases the risk for deadly cancers and cardiovascular diseases.”
No comments:
Post a Comment